Speaker Profile
Ph.D., President, Parker Inst. for Cancer Immunotherapy
Biography
Ira Mellman (FAACR, FAIO) began his career at Yale School of Medicine, serving as Sterling Professor of Cell Biology and Immunobiology, Scientific Director of the Yale Comprehensive Cancer Center, and member of the Ludwig Institute for Cancer Research. A National Academy of Sciences member, he is renowned for discovering endosomes, their role in antigen presentation, and the function of dendritic cells in immunity and vaccine responses, building on his fellowship with Ralph Steinman at The Rockefeller University. At Genentech/Roche, where he spent 17 years as VP of Research Oncology and Cancer Immunology, Ira established the cancer immunotherapy franchise responsible for Tecentriq® and Lunsumio®. He also led efforts in personalized cancer vaccines (with BioNTech), cell/cytokine therapies, and tumor microenvironment research. He introduced the Cancer Immunity Cycle (Mellman et al., Nature 2011, 2023), now a foundational concept in immune-oncology. He has served on the boards of the American Cancer Society and the Society for the Immunotherapy of Cancer, receiving their Lloyd J. Old and Richard Smalley Awards. Ira is currently the co-founder and CSO of Medici Therapeutics, a next-generation immunotherapy company. Aded to jot form
Session Abstract – PMWC 2027 Silicon Valley
Davos of Precision Medicine
PMWC 2027 Program
January 27–29, 2027 · Santa Clara Convention Center
Swipe speakers · Tap a card for sessions →
In a few words.
PMWC is indeed The Davos of Biotech
PMWC Hall of Impact
Previous Speakers Include
Nobel laureates, technology founders, regulators, CEOs and scientific pioneers who have taken the PMWC stage.
